JAMMU: Council for Scientific and Industrial Research (CSIR) has launched BGR-34 -country’s first anti-diabetic Ayurvedic drug with DPP4 inhibitory Activity.
BGR-34, designed for type 2 diabetes mellitus has been scientifically validated for its efficacy and safety. BGR-34 is developed jointly by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), the research units of CSIR, Government of India situated at Lucknow. Passing its larger benefits to people, BGR-34 has been economically priced at Rs. 5 per tablet as compared to latest DPP4 inhibitors globally. Its’ now available on all major chemist counters of Punjab, Haryana , Chandigarh and adjoining states of HP and J and K.
Dr. A.K.S Rawat, Senior Principal Scientist, CSIR-NBRI opined that “6 crore of the adult Indian population has been found to be diabetic and there is no effective solution for diabetes as yet. We are sure that eminent medical professionals will recommend it to their patients suffering from type 2 Diabetes mellitus for quicker and consistent response. The modern diabetes drugs are known for side-effects and toxicity while BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs.”
Formulation of this drug of is a result of a novel joint research from the National Botanical Research Institute (NBRI) & Central Institute for Medicinal and Aromatic Plants (CIMAP), the research units of Council of Scientific and Industrial Research (CSIR), Govt. of India for the comprehensive, effective and safe management of type-II diabetes with a difference Mr. K. K. Sharma, Managing director of AIMIL Pharmaceuticals, said “We are happy to be partner with institutes of such repute for passing on its benefits to the people. We have decided to launch this marvellous anti-diabetic product in the brand name BGR-34, standing for Blood Glucose Regulator with 34 identified active phyto-constitutents from herbal resources. With a strong marketing distribution network spread all over the country, Aimil is strongly committed to carry forward the marvellous benefits of this novel research to the suffering masses all throughout the country and abroad.”
Aimil Pharmaceuticals, already had one successful technological collaboration with DRDO (Defence Research and Development Organization, Govt. of India) yet another premier research institute in the country, for effective and safe treatment of leukoderma, still considered to be a big challenge to address. The product for leucoderma was successfully launched in the market in the name Lukoskin, bringing smiles for the patient suffering from the social stigma, leucoderma.
In appreciation to its research work and commitment to develop high quality innovative drugs, Aimil Pharmaceuticals has been bestowed with 3 national awards from Govt. of India for manufacturing herbal medicines of the quality and also for research and development activities.